NEW YORK, Feb. 27, 2017 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Argos Therapeutics, Inc. (NASDAQ: ARGS). On February 22, 2017, an independent data monitoring committee recommended that Argos discontinue its Phase 3 ADAPT clinical trial of rocapuldencel-T for the treatment of metastic kidney cancer. Following this news, shares of Argos were down more than 66% on intraday trading on February 22, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.